64 completed. 64 Phase 2, 7 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 64 | Completed 64 |
| Phase 1 | 7 | Completed 7 |
| Phase 3 | 4 | Completed 4 |
Follow Allergic Rhinitis: new trials by email Literature Review of Allergic Rhinitis trials Research Report on Allergic Rhinitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis INI-2004, Placebo - Allergic Rhinitis Due to Allergens, Rhinitis Allergic | Phase 2 | Completed | Inimmune Corporation | 78 | 2026-01-19 | 2026-04-29 |
| Study of CM310 in Patients With Allergic Rhinitis CM310 - Allergic Rhinitis | Phase 2 | Completed | Keymed Biosciences Co.Ltd | 100 | 2023-08-23 | 2024-11-08 |
| A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis Interleukin-4 receptor responders 1, Interleukin-4 receptor responders 2, Placebo - Allergic Rhinitis | Phase 2 | Completed | Beijing Tongren Hospital | 93 | 2022-08-17 | 2023-10-19 |
| Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants REGN5713, REGN5714, REGN5715 - Allergic Rhinitis, Conjunctivitis | Phase 2 | Completed | Regeneron Pharmaceuticals | 217 | 2022-08-15 | 2024-11-19 |
| Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis PA9159 nasal spray solution, 10 μg once daily for 14 days, PA9159 nasal spray solution, 20 μg once daily for 14 days, PA9159 nasal spray solution, 40 μg once daily for 14 days - Allergic Rhinitis | Phase 2 | Completed | Anhui Palo Alto Pharmaceuticals, Inc. | 204 | 2022-04-15 | 2023-02-01 |
| The Effects of Using Yupingfeng Powder with Variation for the Treatment of Allergic Rhinitis Yupingfeng Powder granules, Placebo - Allergic Rhinitis | Phase 2 | Completed | Prof. Lin Zhixiu | 58 | 2022-04-12 | 2024-11-07 |
| AllerPops Reduce Nasal Symptoms in Adult Volunteers With Allergic Rhinitis AllerPops - Allergic Rhinitis | Phase 2 | Completed | AllerPops Corp | 72 | 2022-04-05 | 2023-07-24 |
| Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract Polvac Grass+Rye, Saline 0.9% - Rhinitis, Allergic, Seasonal, Rhinitis; Allergic, With Asthma | Phase 1 / Phase 2 | Completed | University of Zurich | 60 | 2022-02-10 | 2025-05-21 |
| A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis azelastine/fluticasone 137/50 mcg nasal spray, Dymista™ - Allergic Rhinitis | Phase 2 | Completed | Synmosa Biopharma Corp. | 136 | 2020-08-20 | 2023-09-25 |
| Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis Eye Drops, Solution in Single-Dose Container - Allergic Conjunctivitis, Allergic Rhinitis | Phase 2 | Completed | Marinomed Biotech AG | 64 | 2020-08-04 | 2022-08-25 |
| Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis Norketotifen, Placebo - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 2 | Completed | Emergo Therapeutics, Inc. | 36 | 2019-04-01 | 2020-08-21 |
| Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis AD17002, Formulation Buffer - Allergic Rhinitis | Phase 1 / Phase 2 | Completed | Advagene Biopharma Co. Ltd. | 48 | 2019-03-26 | 2025-09-16 |
| Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy Dupilumab, Timothy Grass SCIT, Placebo matching dupilumab - Allergic Rhinitis | Phase 2 | Completed | Regeneron Pharmaceuticals | 103 | 2018-06-07 | 2020-05-28 |
| Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass ALK Alutard 5-grasses and birch, ALK Diluent - Allergic Rhinitis | Phase 1 / Phase 2 | Completed | Lars Olaf Cardell | 34 | 2018-05-15 | 2022-09-21 |
| Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients Prapchompoothaweep remedy, Loratadine 10 Mg - Allergic Rhinitis, Adverse Drug Event | Phase 2 | Completed | Thammasat University | 72 | 2017-11-23 | 2018-08-22 |
| Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis B244 suspension, Vehicle - Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen | Phase 1 / Phase 2 | Completed | AOBiome LLC | 71 | 2017-09-19 | 2022-11-25 |
| Benjakul Extract and Loratadine for Treatment Allergic Rhinitis Patients Benjakul Extract, Loratadine - Allergic Rhinitis | Phase 2 | Completed | Thammasat University | 60 | 2017-07-30 | 2018-04-26 |
| A Novel Biologic Therapy for Perennial Allergic Rhinitis Allergen Immunotherapy Extract, Allergen Immunotherapy Control - Allergic Rhinitis | Phase 2 | Completed | Johns Hopkins University | 31 | 2016-12-19 | 2019-09-04 |
| Clinical Response to Rhinovirus Challenge Rhinovirus (GMP RV16 HRV-16) - Asthma, Allergic Rhinitis | Phase 2 | Completed | University of Virginia | 38 | 2016-09-01 | 2024-01-09 |
| ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen AllerT, placebo - Allergic Rhinitis | Phase 2 | Completed | Anergis | 421 | 2016-09-01 | 2018-01-10 |
Showing 20 of 64. Sign in to see all of them.
Rhinitis, Allergic (64) · Rhinitis, Allergic, Seasonal (7) · Asthma (5) · Rhinitis (5) · Hypersensitivity (3) · Conjunctivitis (2) · Eczema (2) · Sneezing (2) · Conjunctivitis, Allergic (1) · Drug-Related Side Effects and Adverse Reactions (1) · Dust Mite Allergy (1) · Food Hypersensitivity (1) · Nasal Obstruction (1) · Rhinitis, Allergic, Perennial (1) · Rhinorrhea (1)
Hypersensitivity, Immediate (64) · Immune System Diseases (64) · Nose Diseases (64) · Otorhinolaryngologic Diseases (64) · Respiratory Hypersensitivity (64) · Respiratory Tract Diseases (64) · Hypersensitivity (61) · Rhinitis (59) · Infections (6) · Respiratory Tract Infections (6) · Bronchial Diseases (5) · Lung Diseases (5) · Lung Diseases, Obstructive (5) · Conjunctival Diseases (2) · Dermatitis (2)
Fluticasone (3) · (5-fluoro-2-methyl-3-quinolin-2-ylmethylindo-1-yl)acetic acid (2) · Cetirizine (2) · Desensitization, Immunologic (2) · Loratadine (2) · Probiotics (2) · Serum Albumin, Human (2) · azelastine (2) · fexofenadine (2) · (4-cyclobutyl-(1,4)diazepan-1-yl)-(6-(4-fluorophenoxy)pyridin-3-yl)methanone (1) · 3-fluoro-3-(3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl)-N-(2-methylpropyl)cyclobutanecarboxamide (1) · 6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide (1) · AZD8848 (1) · Budesonide (1) · GSK 1004723 (1)
HAL Allergy (5) · Novartis Pharmaceuticals (3) · Thammasat University (3) · Anergis (2) · AstraZeneca (2) · GlaxoSmithKline (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · National University Hospital, Singapore (2) · Oxagen Ltd (2) · Pfizer (2) · Regeneron Pharmaceuticals (2) · ALK-Abelló A/S (1) · AOBiome LLC (1) · Advagene Biopharma Co. Ltd. (1) · Alcon Research (1)
United States (11) · Canada (10) · Germany (10) · Sweden (8) · Austria (6) · Poland (4) · United Kingdom (4) · China (3) · Spain (3) · Thailand (3) · Denmark (2) · France (2) · Hong Kong (2) · Lithuania (2) · Singapore (2)
Lennart Greiff, MD, PhD (3) · Dr Lynette Shek, Consultant (2) · Alain Didier, Pr. (1) · Albert Finn, MD (1) · Andrew M Wilson (1) · Araya Satdhabudh, MD (1) · Bertil Andersson (1) · Brad H Goodman, MD (1) · Christian Gessner, M.D. (1) · Christopher Smith, MD (1) · Claus Bachert, PhD, MD (1)
PMID 19001265, PMID 19680119, PMID 22464647, PMID 22994348, PMID 23025511, PMID 24388010, PMID 24852424, PMID 24934402, PMID 24986270, PMID 25024716, PMID 26133030, PMID 26272281, PMID 26342289, PMID 26417901, PMID 26682038, PMID 27231527, PMID 27253988, PMID 29168570, PMID 30391954, PMID 32679209, PMID 33099797, PMID 33647073, PMID 34187620, PMID 34429614, PMID 34429875, PMID 34791679, PMID 35031416, PMID 36588672, PMID 38279910, PMID 38322553, PMID 38356731, PMID 39035788, PMID 39386177, PMID 40420199
2009 (1), 2019 (1), U01AI123337 (1)